Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.

This article discusses research on the effect of a glycoprotein CD33-specific retargeting of cytotoxic effector T cells on hematopoiesis. Researchers performed both chromium release and flow cytometry-based assays to evaluate the functional efficacy of the novel humanized bispecific antibody CD33-CD3. They discovered that CD33-CD3 is capable of redirecting human T cells efficiently toward CD33 + acute myeloid leukemia (AML) blasts.